Patent intelligence · US
US 11026978
Compositions and methods for treating multiple sclerosis and related disorders
Compositions and methods for treating multiple sclerosis and related disorders
Patent details — US 11026978
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 8, 2021
- Expiration
- Jun 3, 2041
- Applicant
- Finch Therapeutics Holdings LLC
- Claims
- 20
- CPC classes
- A61K, A61K35/38, A61K9/0053, A61P
Quick answer
US 11026978 (Compositions and methods for treating multiple sclerosis and related disorders) is held by Finch Therapeutics Holdings LLC. Status: granted. Granted Jun 8, 2021. Expires Jun 3, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Finch Therapeutics Holdings LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K35/38, A61K9/0053, A61P, A61P25/28
More from Finch Therapeutics Holdings LLC
Related pharmaceutical patents in our USPTO index.
-
US 12390496
Methods for treating ulcerative colitis
granted -
US 12350298
Microbiome related immunotherapies
granted -
US 12290538
Methods and products for treatment of gastrointestinal disorders
granted -
US 12285447
Methods and compositions for treating ulcerative colitis
granted -
US 12161678
Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
granted -
US 12005086
Microbiome related immunotherapies
granted -
US 11911419
Compositions and methods for treating epilepsy and related disorders
granted -
US 11890308
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
granted
Frequently asked questions
What is US patent 11026978?
US 11026978 (Compositions and methods for treating multiple sclerosis and related disorders) is held by Finch Therapeutics Holdings LLC. Status: granted. Granted Jun 8, 2021. Expires Jun 3, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11026978?
Finch Therapeutics Holdings LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 33 pharmaceutical patents for this assignee.
When does US 11026978 expire?
Our index shows an expiration date of Jun 3, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.